Specialty Pharmacy

Bill Sullivan of the Specialty Pharmacy Association of America describes the growth of the specialty pharmacy industry and the factors that prompted the formation of SPAARx.

Prime Therapeutics Specialty Pharmacy LLC helped 4 in 10 members save on their drug costs by informing them of copay coupon and patient assistance programs (PAP) and applying them to their prescriptions, according to new research presented by pharmacy benefit manager Prime Therapeutics LLC (Prime).

Today, more than 30 pharmacy organizations across the globe will go on Twitter for American Pharmacists Month.

Rheumatologists in Austria and The Netherlands have proposed a reclassification of synthetic disease-modifying antirheumatic drugs (DMARDs) into targeted synthetic DMARDs and conventional synthetic DMARDs.

The 2014 10th Annual Specialty Pharmacy Summit & Expo, Hosted by Armada Health Care, is pleased to announce that individual attendee registration is now open for the conference.

Avella Specialty Pharmacy has been chosen by Navitus Health Solutions LLC to provide Synagis to its managed Medicaid members in Texas and Colorado.

Pertuzumab (Perjeta) in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer.

Investigators in the Czech Republic have found an association between soft tissue lesions and diminished survival in patients with multiple myeloma.

Managed Health Care Associates, Inc (MHA) is pleased to announce that the latest release of RxPertise Consulting Software.

The Generic Pharmaceutical Association petition recommends that the FDA use the active ingredient in a reference biologic when naming a biosimilar product.

The FDA has added a new black box warning to 2 drugs, rituximab (Rituxan) and ofatumumab (Arzerra) for the potential of either drug to cause reactivation of hepatitis B virus (HBV).

Leaders from the Senate and House committees overseeing health policy announced that they have reached an agreement on legislation to help ensure the safety of compounded drugs and our nation's pharmaceutical supply chain.

Manufacturers often select their specialty drug distribution strategy based on the level of REMS reporting required by the FDA. What are some things keeping specialty pharmacies and manufacturers from collecting the data they truly want?

Michael Einodshofer of Walgreens identifies the various charges that can be included in the total cost of an infusion in a hospital setting.

In response to the lobbying efforts of SPAARx and other industry organizations over the past months, the Department of Health and Human Services (HHS) provided revised guidance on remuneration for refill reminders and other similar communications.

Health care reform will undoubtedly change the way specialty drugs are managed within the distribution supply chain, and specialty pharmacy providers may soon be competing with hospitals for patient share.

Between 21% and 28% of patients taking an oral therapy for hepatocellular carcinoma (HCC) were nonadherent to treatment. Certain groups of patients may benefit from counseling services that promote improved adherence.

A study compared historical and contemporary multiple sclerosis cases to determine how first-generation disease-modifying drugs affected disease progression.

Seniors have medication needs that cannot sufficiently be met by mail-service pharmacy, a recent study in the Journal of Managed Care Pharmacy suggests.

The Patients' Access to Treatments Act of 2013 proposes limits on patients' costs for specialty drugs.

Data from a national survey on community health in racial and ethnic groups suggest specific socioeconomic barriers to hepatitis C virus detection and therapy.

Armada Health Care and the Specialty Pharmacy Association of America (SPAARx) today announced their support of 2 key initiatives of the Academy of Managed Care Pharmacy (AMCP).

Armada welcomes interested industry experts to submit speaker proposals to join the prestigious faculty for the 10th Annual Specialty Pharmacy Summit & Expo, May 5-9, 2014.

MHA announced today that it has entered into a strategic alliance with CoverMyMeds to help facilitate a more efficient process for completing and submitting drug prior authorizations (PAs).

After promising results from early studies, investigators have received approval to start testing daratumumab in patients with multiple myeloma.

A recent trial supports noninferiority of pazopanib and sunitinib in terms of efficacy, with fewer adverse events associated with patient discomfort occurring with pazopanib than with sunitinib.

Inflectra was approved for treatment of inflammatory conditions by the European Medicines Agency based on evidence that it was as effective, safe, and tolerable as its reference drug, Remicade.

UHC, an alliance of the nation's leading nonprofit academic medical centers, is unveiling a new specialty pharmacy program in late 2013/early 2014 to provide patients with access to the specialty medications they need at the hospitals where they are treated.

Carrie Hurwitz, MBA, director, corporate strategy and business development at McKesson, explains why pharmacists may be the health care providers best positioned to recruit patients into clinical trials.

Magellan Health Services Inc. announced it has entered into an agreement to acquire Partners Rx, a privately held, full-service commercial pharmacy benefits management company for $100 million.